- Research article
- Open Access
Ionizing radiation modulates the phenotype and function of human CD4+ induced regulatory T cells
BMC Immunology volume 21, Article number: 18 (2020)
The use of immunotherapy strategies for the treatment of advanced cancer is rapidly increasing. Most immunotherapies rely on induction of CD8+ tumor-specific cytotoxic T cells that are capable of directly killing cancer cells. Tumors, however, utilize a variety of mechanisms that can suppress anti-tumor immunity. CD4+ regulatory T cells can directly inhibit cytotoxic T cell activity and these cells can be recruited, or induced, by cancer cells allowing escape from immune attack. The use of ionizing radiation as a treatment for cancer has been shown to enhance anti-tumor immunity by several mechanisms including immunogenic tumor cell death and phenotypic modulation of tumor cells. Less is known about the impact of radiation directly on suppressive regulatory T cells. In this study we investigate the direct effect of radiation on human TREG viability, phenotype, and suppressive activity.
Both natural and TGF-β1-induced CD4+ TREG cells exhibited increased resistance to radiation (10 Gy) as compared to CD4+ conventional T cells. Treatment, however, decreased Foxp3 expression in natural and induced TREG cells and the reduction was more robust in induced TREGS. Radiation also modulated the expression of signature iTREG molecules, inducing increased expression of LAG-3 and decreased expression of CD25 and CTLA-4. Despite the disconcordant modulation of suppressive molecules, irradiated iTREGS exhibited a reduced capacity to suppress the proliferation of CD8+ T cells.
Our findings demonstrate that while human TREG cells are more resistant to radiation-induced death, treatment causes downregulation of Foxp3 expression, as well as modulation in the expression of TREG signature molecules associated with suppressive activity. Functionally, irradiated TGF-β1-induced TREGS were less effective at inhibiting CD8+ T cell proliferation. These data suggest that doses of radiotherapy in the hypofractionated range could be utilized to effectively target and reduce TREG activity, particularly when used in combination with cancer immunotherapies.
A variety of immunotherapeutic agents are being used to treat advanced malignancies and CTLA-4 and PD-1/PD-L1 T cell checkpoint blocking antibodies are currently the most common approach. Efficient tumor control by immunotherapies relies on robust CD8+ cytotoxic T lymphocyte (CTL) activity [1,2,3] and these immune checkpoint blocking (ICB) antibodies release the inhibitory pathways restraining the action of CTLs. While the most effective immunotherapies in development seek to generate, promote, or stimulate tumor-specific CTLs, tumors often induce an immunosuppressive microenvironment that allows them to evade immune cell killing . A major mechanism of tumor-induced immunosuppression is the recruitment and/or induction of CD4+ regulatory T cells (TREGS) within the tumor microenvironment [5, 6].
TREGS are a suppressive subset of CD4+ T cells important for preventing autoimmunity . These cells are characterized by expression of the high affinity IL-2 receptor, CD25, and the transcription factor forkhead box p3 (Foxp3) . TREGS can be naturally derived in the thymus (nTREG), or they can be induced in the periphery from naïve CD4+ precursors (iTREG) [5, 9, 10]. Several cancer types are known to contain high levels of TREGS that facilitate escape from immune surveillance [11,12,13]. To maintain an immunosuppressive microenvironment tumor cells have been reported to recruit peripheral TREGS as well as induce conversion of CD4+ conventional T cells (TCONV) into TREGS within the tumor [13,14,15,16,17]. Though nTREG and iTREG cells both have suppressive function, iTREGS reportedly have less stable Foxp3 expression due to partial demethylation of CpG motifs within the foxp3 locus . Functionally, TREGS are capable of inhibiting the proliferation and killing activity of CTLs through several mechanisms including: [a] secretion of transforming growth factor-β1(TGF-β1) and IL-10, [b] metabolic disruption through CD39 and CD73 , or [c] contact-dependent inhibition via cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), lymphocyte activation gene 3 (LAG-3), and programmed death ligand 1 (PD-L1) signaling [20, 21].
Ionizing radiation (IR) remains a common treatment modality for most cancer types and is often used in combination with cancer immunotherapy-based strategies when radiation alone is insufficient to eradicate advanced disease . Interestingly, radiation has been shown to enhance anti-tumor immune responses by several mechanisms. Research in our lab, and others, has shown that tumor cells exposed to doses within the hypofractionated range of radiation increase the expression of several cell surface proteins on tumor cells that are important for immune attack. Major histocompatibility (MHC) class I, death receptors (Fas/CD95 and TRAIL/CD253), and effector T cell costimulatory molecules (OX40L and 4-1BBL) exhibit increased expression on tumor cells surviving radiation [23,24,25,26]. Expression of these molecules subsequently promotes increased sensitivity to killing by CTLs [27, 28]. Induction of immunogenic cell death (ICD) is another mechanism of immune enhancement by radiation that results in stimulation of antigen presenting cells that can promote and drive an adaptive anti-tumor immune response . In addition to local tumor control via DNA damage and cell death, radiation treatment can cause abscopal effects that result in immune control of tumors that are outside of the irradiated field [30, 31]. This phenomenon is being seen more and more frequently with the increased use of radiation in combination with immunotherapies [32, 33].
While much has been reported on the impact of IR on tumor cells, the impact of radiation on the frequency, phenotype, and suppressive function of regulatory immune cells such as TREGS is less well studied. Several murine studies have shown that TREGS are more radioresistant than other lymphocyte populations, however, it is less clear what effect radiotherapy (RT) has on the phenotype and function of human TREGS [34, 35]. Moreover, functional studies in mice have been contradictory. Studies by Qu et al found no difference in the suppressive function of TREGS from radiation treated mice compared to control mice, in contrast, Balogh et al and Billiard et al both reported decreased functional activity of irradiated TREGS [36,37,38]. In addition, studies by Muroyama et al and Kachikwu et al reported increased TREG numbers in locally irradiated tumors compared to control mice, in vivo [39, 40]. However, Cao et al (2009) and Liu et al observed decreased frequencies of human TREGS irradiated in vitro and murine TREGS following whole body irradiation in vivo, respectively [41, 42]. Many factors could contribute to the different outcomes reported among these studies, including differences in radiation dose used, time of evaluation after radiation, local irradiation versus whole body irradiation, and tumor-bearing versus non-tumor bearing model systems.
To more specifically extend these observations towards clinically relevant tumor immunity we sought to determine the impact of hypofractionated doses of radiation on induced human TREGS, as these are most likely to accumulate at tumor sites. We first assessed the direct effect of radiation on the viability and expression of Foxp3 in both nTREG and iTREG cells. We also evaluated the impact of radiation on the suppressive function of iTREGS and the expression of molecules associated with TREG functional activity: CD25, CTLA-4, LAG-3, CD39, CD73, and PD-L1. Our data reveal that radiation induces similar levels of death among human nTREGS and iTREGS, but that less death occurs in TREGS as compared to CD4+ TCONV cells. We also found that radiation decreases expression of Foxp3 in both types of TREG cells but that Foxp3 expression is more robustly reduced by radiation in iTREGS. Additionally, we show that iTREG cell phenotype is directly modulated by radiation and that these cells are functionally less suppressive following radiotherapy.
Both natural TREG and induced TREG cells are more resistant to cell death by radiation than CD4+ conventional T cells
It has been reported that TREG cells preferentially survive radiation treatment compared to CD4+ conventional T (TCONV) cells in mice [36, 43, 44]. In contrast, experiments utilizing human cells observed increased sensitivity of TREGS to low dose radiation (< 2 Gy) . Most studies exploring this question have investigated the sensitivity of natural TREGS (nTREGS) alone or the total TREG population in vivo, which potentially includes both natural and tumor induced TREGS. As such, the specific radio-sensitivity of induced TREG (iTREG) cells has not been fully explored. We first compared the sensitivities of natural and induced human TREGS to determine if there were differences in susceptibility to cell death between them following exposure to a hypofractionated dose of radiation. We isolated CD4 + CD25+ nTREG cells from human peripheral blood mononuclear cells (PBMCs) as described in the Methods. To induce a TREG phenotype, naïve CD4+ T cells were cultured in the presence of TGF-β1 and ATRA for 6 days which resulted in expression of Foxp3 and other TREG associated genes . nTREG, iTREG, or CD4+ TCONV cells were subsequently exposed to 10 Gy of radiation and evaluated 48 h post-treatment for cell death. While CD4+ TCONV cells exhibited significant increases in death after radiation, both nTREG and iTREG cells had lower relative amounts of cell death (Fig. 1). In separate experiments, using 7-AAD to assess viability, CD4+ TCONV cells exposed to a lower dose of radiation (5 Gy) displayed around twice as much cell death as compared to TREGS. Irradiated CD4+ TCONV cells exhibited a 4.5-fold increase in cell death over untreated cells (0 Gy) as compared to irradiated nTREGS that had only a 2.3-fold increase in cell death over untreated cells. Similarly, a 1.6-fold increase in cell death over untreated cells (0 Gy) was detected in iTREGS exposed to 5 Gy, as compared to a 3-fold increase in cell death observed in the control CD4+ TCONV cells. These results support the idea that human TREG cells are more radio-resistant as compared to CD4+ TCONV cells when exposed to radiation in the hypofractionated dose range.
Radiation decreases Foxp3 expression more robustly in iTREGS as compared to nTREGS
TREG cells express the transcription factor Foxp3, a master regulator essential for their development and suppressive function . Foxp3 is the most commonly used marker for identification of TREGS, and while both nTREG and iTREG cells express it, Foxp3 expression is reportedly less stable in iTREGS . Therefore, it seemed plausible that nTREGS and iTREGS could have differential phenotypic stability following radiation treatment. Similar to studies describing the sensitivity of TREGS to cell death following irradiation, most of the studies examining Foxp3 expression have been performed in mice. Murine studies have reported both an increase [39, 40] and decrease  in TREG frequency following radiation, while data evaluating human TREG cells noted a dose dependent reduction in Foxp3 expression . Additionally, in vivo experiments performed in disease settings in mice evaluated the total TREG population which, again, could contain both types of TREG cells. In contrast, studies evaluating phenotypic changes in human cells after irradiation have been limited to nTREG cells. Here, we evaluated human natural and induced TREGS for Foxp3 expression following exposure to a single hypofractionated dose of radiation, in vitro. Foxp3 expression in CD4 + CD25+ nTREGS decreased after treatment with 10 Gy (Fig. 2a). Foxp3 was expressed in 88% of untreated cells on average and significantly decreased to 68% in cells treated with radiation across three independent experiments (Fig. 2b). In general, more cells expressed Foxp3 in nTREGS as compared to iTREG (Fig. 2c), however, Foxp3 expression was further reduced in iTREGS from 48% (0 Gy) to 8% (10 Gy) following radiation treatment across independent experiments (Fig. 2d). iTREG cells are characterized as expressing high levels of CD25. Evaluation of the CD4 + CD25hi population of iTREGS revealed that Foxp3 was more highly expressed in the untreated cells of this population (69%) and that 10 Gy radiation still significantly decreased Foxp3 expression within CD25hi iTREGS (10%) (Fig. 2e). Interestingly, the magnitude of decreased Foxp3 expression was greater within the CD4 + CD25hi population (Fig. 2e) as compared to that observed in the total CD4 + CD25+ iTREG population (Fig. 2d). The percent of total CD4+ T cells remained unchanged with treatment suggesting that radiation specifically downregulates the expression of Foxp3 (data not shown). Compared to untreated cells, both nTREGS and iTREGS showed a significant decrease in Foxp3 expression 48 h after exposure to 10 Gy. Interestingly, iTREGS showed a more robust decrease in Foxp3 expression when compared to nTREGS suggesting that they are more sensitive to the effects of radiation.
Irradiated iTREGS are not converted to TH1 or TH2 cells following loss of Foxp3
Plasticity is a unique characteristic of CD4+ T cells, allowing them to differentiate from one T helper (TH) subset to another when exposed to the right cytokine milieu . Additionally, epigenetic changes in transcription factor activity induce changes in the type of CD4+ T cell needed for the appropriate immune response . Foxp3 is induced in TREG cells to limit cell cytotoxicity and autoimmunity . The transcription factors T-box transcription factor (T-bet) and GATA binding protein 3 (GATA3) drive TH1 and TH2 differentiation, respectively . Because changes in the microenvironment can directly influence the phenotype of local CD4+ T cells , we sought to determine if irradiated iTREGS were being converted into another TH subset upon downmodulation of Foxp3 expression. While radiation robustly reduced Foxp3 expression in CD4 + CD25+ iTREG cells (42 to 18%), expression of TH1-associated T-bet or TH2-associated GATA3 did not exhibit a compensatory increase in expression 48 h post-treatment (Fig. 3). Interestingly, while T-bet expression was low and remained low after radiation, GATA3 expression was detected in a subpopulation of untreated cells and its expression was also reduced by radiation. These data suggest that while radiation can reduce expression of transcription factors in CD4+ T cells, irradiated Foxp3+ iTREG cells are not converted into a TH1 or TH2 subset but instead can be described as an “ex-Foxp3+” CD4+ T cell.
Radiation induces differential changes in signature TREG molecules
In addition to Foxp3, TREG cells express several signature molecules associated with their regulation and functional activity. CD25, the high-affinity IL-2 receptor, is highly expressed by iTREGS. CD25 expression can be enhanced in TREG cells by Foxp3 binding at the Cd25 promoter . Because we observed a decrease in Foxp3 following radiation treatment we wanted to determine if CD25 expression was also reduced. We first evaluated CD25 expression in CD4+ TCONV cells and detected a moderate reduction in expression in irradiated cells compared to untreated cells, however, the change was not significant (Fig. 4a). In contrast, when iTREGS were evaluated we observed a significant decrease in CD25 expression in irradiated cells as compared to untreated cells (Fig. 4b). This reduction in CD25 expression could be detected within the total CD4 + CD25+ population (upper right quadrant), as well as the CD4 + CD25hi population (inset box gate)(Fig. 4c).
Because CD4 + CD25hi iTREG cells had the highest frequency of Foxp3+ cells (Fig. 2e), we further interrogated this cell population for the expression of other surface proteins associated with TREG suppressive function. Cytotoxic T lymphocyte antigen 4 (CTLA-4) and lymphocyte activation gene 3 (LAG-3) have been shown to block dendritic cell maturation and inhibit effector T cell proliferation [20, 54,55,56]. Concordant expression of the ectoenzymes CD39 and CD73 suppress effector T cell function by converting ATP into adenosine . Furthermore, the presence of PD-L1+ TREGS has been correlated with exhausted effector T cells and a suppressive tumor microenvironment . CTLA-4 has been reported to be regulated by Foxp3 [57, 58]. Thus, we next sought to determine if its expression would also be reduced following radiation and found significant down-regulation of its expression from 57 to 44% across independent experiments (Fig. 4d). While LAG-3 has been reported to be regulated by Foxp3, its expression has also been detected in Foxp3-negative regulatory T cells [57, 59]. In contrast to the radiation-induced reduction seen in CD25 and CTLA4, LAG-3 expression was moderately increased across replicate experiments (34 to 48%) within the CD4 + CD25hi population of cells (Fig. 4e). CD73 expression was also moderately increased though the change was not significant (20 to 28%) (Fig. 4g). CD39 was expressed in approximately half of the cells (Fig. 4f) while PD-L1 was expressed in all iTREG cells (Fig. 4h). Radiation had no effect on the percent of cells expressing CD39 or PD-L1, however a small reduction in PD-L1 density was seen (Fig. 4i). These results suggest that radiation is capable of disconcordantly modulating the expression of iTREG-associated suppressive proteins. In addition, our findings suggest that Foxp3 regulated genes may be the most sensitive to down-regulation by radiation, and that LAG-3 is likely not regulated by Foxp3 in human iTREGS.
Not all cells in the CD4 + CD25hi population expressed Foxp3 (Fig. 2e) so we next evaluated changes in TREG suppressive molecule expression within Foxp3+ cells following radiation treatment. For this analysis iTREGS were defined as CD4 + Foxp3+ (Fig. 5a, upper right quadrant) and the expression of suppressive molecules after radiation was measured within this population of cells. Similar to the change detected in CD4 + CD25hi cells (Fig. 4c), the expression of both CD25 (Fig. 5b) and CTLA-4 (Fig. 5c) was decreased after radiation in CD4 + Foxp3+ cells, though the modulation did not reach statistical significance. Likely because these cells were selected for expression of Foxp3, which regulates their expression. We did, however, detect a significant increase in LAG-3 expression within this cell population (Fig. 5d), as well as an increase in CD73 that neared statistical significance (Fig. 5f). Again, radiation did not alter the frequency of CD4+Foxp3+ T cells expressing either CD39 or PD-L1 (Fig. 5e and Fig. 5g) but did induce a small reduction in the density of surface PD-L1 (Fig. 5h). Overall, analysis of both CD4 + CD25hi and CD4 + Foxp3+ iTREGS revealed that radiation reduced expression of CTLA-4 and CD25, while conversely increasing expression of LAG-3 and CD73. However, little change in the expression of CD39 or PD-L1 was induced by in vitro irradiation in either cell population.
Radiation inhibits suppressive activity of iTREGS
We observed that radiation treatment reduced the expression of Foxp3 in iTREG cells and that the expression of molecules, associated with their ability to suppress other immune cells, could be modulated both positively and negatively by IR. We next wanted to directly investigate how the suppressive function of iTREG cells was affected by radiation. We compared the ability of irradiated and non-irradiated iTREGS to inhibit the proliferation of CD8+ T cells. Forty-eight hours after treatment with radiation, viable iTREGS were counted and co-incubated with autologous CFSE-labeled CD8+ T cells at the indicated ratio. After 5 days of co-culture, the proliferation of CD8+ T cells was measured by CFSE dilution. Ninety percent of stimulated CD8+ cells underwent cell division as indicated by reduced levels of intracellular CFSE (Fig. 6a). Proliferation of these cells was greatly reduced when iTREGS were added. In addition to the percent of proliferating cells being reduced from 93 to 65%, the number of cells exhibiting more than three divisions was also reduced. In contrast, when TREGS treated with 10 Gy were added the proliferation of CD8+ cells was similar to that observed in control cells (92%). Across replicate experiments, CD8+ T cells had a mean proliferation rate of 90% in the presence of 10 Gy treated iTREGS, as compared to only 74% following co-culture with non-irradiated iTREG cells (Fig. 6b; p = 0.0280). Thus, iTREG cells surviving 10 Gy of ionizing radiation exhibit reduced capacity to suppress the proliferation of autologous CD8+ T cells.
RT is a common treatment modality for cancer and is well documented to enhance antitumor immune responses by modulating tumor phenotypes, making them more susceptible to killing by CTLs . The activity of CTLs, however, can be limited by suppressive TREGS. The effect of radiation directly on TREG biology remains controversial and there are very few reports evaluating human TREG cells. While T cells are known to be sensitive to high doses of radiation, the increased use of lower radiation doses per fraction, such as those used during hypofractionated radiotherapy, necessitates the need to elucidate the effects of radiation on T cells surviving RT exposure. In this study, we compared the effect of radiation treatment on human natural and induced TREG cell viability and Foxp3 expression. We show that irradiated human nTREG and iTREG cells are more viable than irradiated CD4+ TCONV cells, and that CD4 + CD25+ TREG cells exhibit decreased expression of Foxp3 after exposure to ionizing radiation. We then extended our studies to further examine how the phenotype and function of iTREG cells are impacted by radiation as these are likely the cells that accumulate in advanced cancers during immune escape. We demonstrate that molecules associated with TREG suppressive function are differentially modulated by radiation and that the suppressive function of iTREGS is inhibited.
Results here, using human cells, are in line with previous reports in mice demonstrating that TREG cells are more resistant to radiation-induced cell death compared to CD4+ TCONV cells [34, 44]. Additionally, we found that this resistance exists in both nTREG and iTREG cells (Fig. 1). Curiously, these results contrast those reported in a previous study assessing human TREGS  exposed to much lower doses of radiation (0.94 Gy and 1.875 Gy). The authors reported significantly more cell death in TREGS as compared to CD4+ TCONV cells . Radiation decreases human CD4+ T cell viability in a dose-dependent manner  and cells exposed to 5 Gy of radiation exhibit a robust decrease in live cells not detected in cells treated with ≤2 Gy. Therefore, it is plausible that human TREGS are relatively more resistant to higher doses (> 2 Gy) of radiation since low dose radiation (≤ 2 Gy) did not induce significant death in CD4+ TCONV cells. In the current study we selected doses, above 2 Gy, that would be relevant to those given per fraction during cancer therapy with hypofractionated RT. Moreover, most studies demonstrating the ability of RT to serve as an adjuvant for anti-tumor immunity point towards a benefit from moderate doses, around 5–12 Gy, being superior than lower 2 Gy fractions.
Much of what is known about the impact of radiation on TREGS has been derived from murine models and both increased and decreased TREG frequencies have been reported following radiation [39,40,41,42]. In studies evaluating TREG frequency in mice, the use of whole-body versus local radiation treatment appears to have a profound effect on the number of TREGS detected. Mice treated with low-dose total body irradiation (1.25 Gy) exhibited a decrease in the frequency and total number of nodal CD4 + Foxp3+ TREG cells , while mice that received local irradiation (10 Gy and 20 Gy) were found to increase the proportion of tumoral and splenic TREGS [39, 40]. It is difficult to know if the changes observed are due to the direct effect of radiation on TREG cells themselves or due to changes induced in tumor cells or another immune cell type in the irradiated area. It is also unclear if the changes are due to TREG cell death, redistribution to another location, or a change in the phenotypic markers used to identify the cells. Our current study, demonstrating the differential sensitivities between CD4+ T cell subsets, support the idea that in vivo observations showing increases in TREGS post-RT may be detecting a decrease in the frequency of conventional CD4+ T cells which are more sensitive to RT than TREGS. Overall, though characterization of immune cell frequencies can provide useful information, details about the functional status of the cells, and expression of suppressive molecules, in diverse tumor model systems would be more informative. Reports of this nature have been limited. Muroyama et al recently reported that isolated tumor and splenic TREGS retained their suppressive function 7 days following local irradiation in B16/F10 tumor-bearing mice . Whether there was an earlier window of time during which TREG function was suppressed was not explored.
Our data reveal a significant decrease in the expression of Foxp3 in human TREG cells 48 h post treatment. This decrease was observed in both nTREG and iTREG cells but was more profound in iTREGS, particularly among CD25hi cells (Fig. 2e). We narrowed our focus to human TGF-β1-induced TREGS as these are likely to be most similar to the tumor-induced TREGS that accumulate during tumor progression and immune escape. Though iTREGS downregulated Foxp3, they did not alter their expression of surface CD4. In addition, the loss of Foxp3 did not appear to be due to conversion to another CD4+ TH subtype as we did not detect an increase in the TH1 or TH2-associated transcription factors T-bet or GATA3 (Fig. 3). Though nTREG and iTREG cells both have suppressive function, iTREGS have been reported to have less stable Foxp3 expression due to partial demethylation of CpG motifs within the foxp3 locus . Demethylation of the foxp3 locus yields the gene accessible to the binding of numerous transcription factors . Radiation can alter the epigenetic enzymes associated with specific gene promotors in cancer cells [63, 64] and has been reported to alter DNA methylation, both globally and in a gene-specific manner . Thus, it seems reasonable that radiation could be altering the epigenetic state of the foxp3 locus, and we would expect iTREGS to be more sensitive to these changes since the region is already partially methylated. Confirmation of this mechanism warrants further investigation. Alternatively, binding of STAT5 to the TREG-specific demethylated region (TSDR) within the conserved noncoding sequence 2 (CNS2) has been shown to stabilize Foxp3 expression , and blockade of the JAK3/STAT5 signaling pathway has been demonstrated to downregulate Foxp3 expression in both human and murine TREG cells . It is possible that radiation alters the expression of STAT5, however, we did not observe any change in phosphorylated STAT5 following radiation treatment (unpublished data) suggesting that radiation-induced regulation of Foxp3 may be independent of STAT5. The CNS2 region, however, is bound by several other transcription factors in addition to STAT5 , and it is possible that radiation modulates the expression of these other factors causing the subsequent reduction in Foxp3 expression.
Beyond Foxp3, expression of CD25, CTLA-4, CD39, CD73, and LAG-3 are commonly associated with TREG phenotype. Additionally, the presence of PD-L1 has been detected on both human  and mouse TREGS , as well as on TGF-β1-induced TREGS . To our knowledge, the effect of radiation on the expression of many of these molecules in human TREGS has not been characterized. TREG cells are commonly defined as being Foxp3+ and CD25hi and we found that CD4 + CD25hi cells were the most significantly reduced following treatment with radiation (Fig. 4). This cell population also exhibited a significant decrease in CTLA-4. This observation is particularly noteworthy because it suggests that, as Foxp3 regulated genes, the reduction in CD25 and CTLA-4 expression may be directly tied to the reduction of Foxp3 expression. Moreover, there was no significant reduction in the expression of the other non-Foxp3 genes associated with TREG phenotype that we evaluated (CD39, CD73, and PD-L1) (Figs. 4 and 5).
We did detect a moderate increase in CD73 and the expression of both CD39 and CD73 can be increased by TGF-β [70, 71]. Though CD73 is expressed intracellularly in humans, surface expression can be induced upon activation with high-dose IL-2 therapy . However, the cells examined in our study exhibited reduced expression of the IL-2 receptor and are likely less responsive to IL-2. Thus, the moderate increase we detected in the expression of CD73 could indicate that there is increased production of TGF-β from the cells. However, the fact that we saw no increase in CD39 expression, which is also sensitive to TGF-β, suggests that another mechanism of regulation may be occurring. Hypofractionated doses of radiation have been shown to increase expression of type I interferon pathway genes associated with an inflammatory signature [73, 74]. While these observations have been made in the context of the whole tumor microenvironment, our data may reveal that radiation can directly alter the cytokines secreted from T cells, which may then modulate CD73 expression.
LAG-3 expression has also been reported to be regulated by Foxp3 , however, it can also be expressed in CD4 + Foxp3-negative cells indicating that it is not strictly dependent on Foxp3 for expression . In our experiments, we were surprised to observe a significant increase in LAG-3 expression by radiation as opposed to the decreased expression of Foxp3, CD25, and CTLA-4 (Fig. 5d). Interestingly, chemo-radiation has been shown to increase the proportion of CD4 + LAG-3+ expressing cells in head and neck cancer patients  demonstrating that this effect may be clinically relevant and detectable. It is possible that radiation is directly altering expression of this gene via epigenetic mechanisms as has been reported for expression of other immune regulatory genes (OX40L and 4-BBL) in irradiated tumor cells . Another possibility is that radiation is altering expression of the transcription factor early growth response gene 2 (Egr2) which has been shown to convert naïve CD4+ T cells into LAG-3-expressing TREGS . Notably, these LAG-3-expressing TREGS were characterized as being Foxp3-negative. Our study demonstrates that radiation induces a CD4 + Foxp3-negative T cell subset from CD4 + CD25hiFoxp3+ iTREGS (“ex-Foxp3+ cells”). While we did not detect conversion of cells towards a TH1 or TH2 subset it remains plausible that radiation treatment converts Foxp3+ iTREGS to another regulatory T cell subset not evaluated here. LAG-3 expression has been reported to confer Foxp3+ regulatory T cells with greater suppressive capacity [20, 56], however, we found that irradiated iTREG cells were functionally less suppressive as compared to untreated cells (Fig. 6), despite a detectable increase in LAG-3 expression. This is in line with reports showing that Egr2-transduced CD4+ T cells, which express LAG-3 and IL-10, insufficiently suppressed proliferation of responder T cells in vitro . Subsequent in vivo studies, however, demonstrated that Egr2-transduced CD4+ T cells did have suppressive capacity which could suggest functional differences in the activity of LAG-3+ cells in vitro versus in vivo. This could indicate that signals, such as MHC Class II, from other immune cells are necessary to stimulate the full suppressive capacity of LAG-3+ TREGS.
How modulation of LAG-3 expression on T cells could impact cancer immunotherapy approaches is worthy of further investigation. LAG-3 expression on CD4+ and CD8+ TCONV cells is known to inhibit their expansion and effector function [77, 78]. As a result, LAG-3 blocking antibodies are currently being tested pre-clinically and clinically, and recent studies have revealed that dual treatment with anti-LAG-3 and anti-PD-1 blocking antibodies can significantly enhance the proliferation of CD4+ and CD8+ TCONV cells . Therefore, the combined use of radiotherapy and anti-LAG-3 blocking antibodies could greatly enhance the antitumor immune response. However, how LAG-3 signaling impacts TREGS remains controversial. In a murine model of Type 1 diabetes, signaling through LAG-3 was shown to limit TREG function  and it is unclear if antagonistic antibodies that prevent LAG-3 signaling could enhance TREG suppressive function at the same time that they are promoting effector T cell activity. Further studies are needed to elucidate the effect that LAG-3 antibodies have on iTREG suppressive function, particularly when used in combination with radiotherapy.
Incorporation of immune-based strategies for the treatment of cancer is becoming increasingly more common in the clinic. Current use is most often for advanced disease where the tumor microenvironment has evolved to favor survival against immune attack. This selection often involves the accumulation of suppressive TREGS that help cancer cells evade immune attack by CTLs. Radiotherapy (RT) has been shown to enhance tumor attack by T cells through multiple mechanisms. RT impacts diverse cells in the microenvironment (tumor cells, immune cells, stromal cells) but the effect of the therapy on each cell type has not been fully elucidated. This is challenging to fully interrogate in vivo, where the impact on the independent cell types is difficult to isolate. A clearer understanding of the direct effects of radiation on suppressive subsets of immune cells can inform optimal strategies for incorporating RT to specifically serve immunotherapy strategies. In this study we found that radiation is capable of directly modulating the expression of Foxp3 and several suppressive surface molecules in human iTREGS. Furthermore, radiation-induced changes resulted in significantly reduced functionality of induced TREGS (Fig. 6). Whether this reduced activity is simply a consequence of the reduced IL-2 signaling capacity due to lower expression of CD25, or from the lower levels of CTLA-4 expression, will require further characterization. It would also be of interest to determine how radiation impacts levels of suppressive molecules that are secreted by TREGS, such as TGF-β1 and IL-10, as well as how long this reduction in suppressive function is retained. Ongoing in vivo studies using radiation-treated tumor-bearing mice also demonstrate reduced TREG numbers after local treatment with hypofractionated doses of RT. Even if only temporary, this reduction in TREGS represents a window of opportunity during which CTL engagement with tumor cells can be manipulated. Given the conflicting observations regarding the role of LAG-3 on TREG biology, future studies will need to determine the functional significance of increased LAG-3 post-RT to elucidate how LAG-3 antibodies in development can be used in combination with RT to most optimally enhance therapeutic efficacy.
In summary, our study found that both human nTREG and iTREG cells are resistant to radiation-induced cell death and that radiation treatment reduces their expression of Foxp3. In addition, we demonstrate that radiation modulates iTREG cell phenotype and inhibits their suppressive activity. These data provide a rationale for the use of radiation to specifically target Foxp3+ iTREG cell function and enhance anti-tumor immune responses in combination with current immunotherapy approaches.
Human T cell isolation
Commercially available human peripheral blood mononuclear cells (PBMCs) were obtained from healthy donors [HemaCare and ATCC]. PBMCs were purified from buffy coats by gradient centrifugation using Lymphocyte Separation Medium [Corning]. PBMCs were rested overnight in RPMI medium containing 10% FBS and 1% Penicillin/Streptomycin prior to T cell isolation by magnetic activated cell sorting (MACS). The CD4+ T cell fraction was isolated by negative depletion from total PBMCs using the human CD4 + CD25+ Regulatory T Cell Isolation Kit [Miltenyi Biotec] according to manufacturers’ instructions. CD25+ natural TREGS (nTREGS) were subsequently positively selected for and separated from the CD4 + CD25- naïve T cell population. Cell purity was assessed by flow cytometry staining. Cells were cultured in a 37 °C incubator with 5% CO2 in TexMACS medium [Miltenyi Biotec]. nTREG and iTREG cells were supplemented with 500 U/mL and 100 U/mL of human recombinant IL-2 [Millipore], respectively.
iTREG differentiation was performed as previously described . Briefly, following MACS isolation, naïve T cells were rested for 2–8 h before plating under iTREG differentiation conditions at 1.1 to 1.5 × 105 cells/well in a U-bottom 96-well plate. Cells were stimulated with 5 μg/mL plate-bound anti-CD3 antibody [OKT3, NA/LE], 1 μg/mL soluble anti-CD28 antibody [CD28.2, NA/LE; BD Biosciences], and 100 U/mL IL-2. Cells stimulated with only these reagents served as “mock” control cells. For iTREG differentiation, 5 ng/mL TGF-β1 [R&D Systems] and 10 nM all-trans retinoic acid [Sigma-Aldrich] were additionally added. On day 3, 100 μL of medium was removed and 100 μL of fresh medium plus growth supplements was added. Cells were then incubated for an additional 3 days.
A RS-2000 biological X-ray irradiator [Rad Source Technology] was used to irradiate cells. Irradiation was performed at a dose of 2 Gy/min at voltage 160 kV and 25 mA current. On day 6, cells were washed and resuspended in fresh TexMACS medium without cytokines. Cells were kept on ice and irradiated (10 Gy) or mock-irradiated (0 Gy). Immediately following irradiation, the culture medium was replaced with fresh medium plus growth supplements minus anti-CD3 and anti-CD28.
Anti-human antibodies were used to characterize TREG cells following isolation: Foxp3-Pacific Blue, Foxp3-PE [PCH101], Gata3-PE [TWAJ] and T-bet-PE [4B10; Invitrogen]; CD4-FITC, LAG-3-PE, CD39-APC and CD73-APC [BD Biosciences]; CD4-APC, CD25-APC, CD25-PE, CTLA-4-APC and PD-L1-APC [BioLegend]. 7-aminoactinomycin D (7-AAD) [BioLegend] or Fixable Viability Stain 780 or 450 [BD Biosciences] were used to exclude dead cells according to manufacturers’ instructions. Appropriate isotype control antibodies were used, and gating was based on < 5% isotype staining. Intracellular staining was performed using the Foxp3 Transcription Factor Staining Buffer Set [Invitrogen] according to manufacturers’ instructions. Data was acquired on a BD Fortessa [Beckman Coulter] and data was analyzed using FlowJo software [TreeStar].
In vitro proliferation assay
Responder T cell proliferation assay was performed as previously described with minor modifications . Briefly, purified CD8+ T cells were labeled with 2.5 μM carboxyfluorescein succinimidyl ester (CFSE) [BD Biosciences]. Labeled CD8s were cultured at a constant number of 6 × 104 cells/well either alone (1:0) or at a 4:1 ratio with either 0 Gy or 10 Gy treated iTREG cells 48 h post radiation in a U-bottom 96-well plate with 5 μg/mL plate-bound anti-CD3 and 1 μg/mL anti-CD28 in TexMACS media for 5 days. Proliferation was determined by CFSE dilution on the flow cytometer and analyzed using FlowJo software.
Statistical differences between groups were calculated using the Student t test or a one-way ANOVA with Tukey’s post-hoc analysis for multiple comparisons using GraphPad Prism software. Statistical significance was defined as P ≤ 0.05. P values: *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001.
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
- TREG :
Regulatory T cell
- TCONV :
T conventional cell
Peripheral blood mononuclear cells
Transforming growth factor beta 1
All-trans retinoic acid
Carboxyfluorescein succinimidyl ester
Cytotoxic T lymphocyte associated protein 4
Lymphocyte activation gene 3
Programmed death ligand 1
Median fluorescence intensity
Conserved noncoding sequence 2
Glucocorticoid- induced tumor necrosis factor receptor
Early growth response gene 2
Immune checkpoint blockade
Fransen MF, Van Der Sluis TC, Ossendorp F, Arens R, Melief CJM. Controlled local delivery of CTLA-4 blocking antibody induces CD8 + T-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin Cancer Res. 2013;19(19):5381–9.
Redmond WL, Linch SN, Kasiewicz MJ. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity. Cancer Immunol Res. 2014;2(2):142–53.
Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti – PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687–95.
Wu AA, Drake V, Huang HS, Chiu SC, Zheng L. Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology. 2015;4(7):1–14.
Su S, Liao J, Liu J, Huang D, He C, Chen F, et al. Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer. Cell Res. 2017;27(4):461–82.
Wiedemann GM, Knott MML, Vetter VK, Rapp M, Haubner S, Fesseler J, et al. Cancer cell-derived IL-1α induces CCL22 and the recruitment of regulatory T cells. Oncoimmunology. 2016;5(9):1–11.
Smigiel KS, Srivastava S, Stolley JM, Campbell DJ. Regulatory T cell homeostasis: steady-state maintenance and modulation during inflammation. Immunol Rev. 2014;259(1):40–59.
Hori S, Nomura T, Sakaguchi S. Control of Regulatory T Cell Development by the Transcription Factor Foxp3. Science. 2003;299(5609):1057–61.
Valzasina B, Piconese S, Guiducci C, Colombo MP. Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res. 2006;66(8):4488–95.
Zhou G, Levitsky HI. Natural regulatory T cells and De novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol. 2007;178(4):2155–62.
Viguier M, Lemaître F, Verola O, Cho M-S, Gorochov G, Dubertret L, et al. Foxp3 expressing CD4 + CD25 high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol. 2004;173(2):1444–53.
Miller AM, Lundberg K, Özenci V, Banham AH, Hellström M, Egevad L, et al. CD4+CD25 high T cells are enriched in the tumor and peripheral blood of prostate Cancer patients. J Immunol. 2006;177(10):7398–405.
Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, et al. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer. 2008;122(10):2286–93.
Ward ST, Li KK, Hepburn E, Weston CJ, Curbishley SM, Reynolds GM, et al. The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer. Br J Cancer. 2015;112(2):319–28.
Kuehnemuth B, Piseddu I, Wiedemann GM, Lauseker M, Kuhn C, Hofmann S, et al. CCL1 is a major regulatory T cell attracting factor in human breast cancer. BMC Cancer. 2018;18(1):1–6.
Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X, et al. Tumor evasion of the immune system by converting CD4+ CD25− T cells into CD4+ CD25+ T regulatory cells: role of tumor-derived TGF-β. J Immunol. 2007;178(5):2883–92.
Mittal S, Marshall NA, Duncan L, Culligan DJ, Barker RN, Vickers MA. Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma. Blood. 2008;111(11):5359–70.
Floess S, Freyer J, Siewert C, Baron U, Olek S, Polansky J, et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol. 2007;5(2):e38.
Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204(6):1257–65.
Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004;21(4):503–13.
Wu SP, Liao RQ, Tu HY, Wang WJ, Dong ZY, Huang SM, et al. Stromal PD-L1–positive regulatory T cells and PD-1–positive CD8-positive T cells define the response of different subsets of non–small cell lung Cancer to PD-1/PD-L1 blockade immunotherapy. J Thorac Oncol. 2018;13(4):521–32.
Jarosz-Biej M, Smolarczyk R, Cichoń T, Kułach N. Tumor microenvironment as a “game changer” in Cancer radiotherapy. Int J Mol Sci. 2019;20(13):3212.
Garnett CT, Palena C, Chakarborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 2004;64(21):7985–94.
Ifeadi V, Garnett-Benson C. Sub-lethal irradiation of human colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways. PLoS One. 2012;7(2):e31762.
Kumari A, Garnett-Benson C. Effector function of CTLs is increased by irradiated colorectal tumor cells that modulate OX-40L and 4-1BBL and is reversed following dual blockade. BMC Res Notes. 2016;9(1):1–14.
Spary LK, Al-Taei S, Salimu J, Cook AD, Ager A, Watson HA, et al. Enhancement of T cell responses as a result of synergy between lower doses of radiation and T cell stimulation. J Immunol. 2014;192(7):3101–10.
Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8 + T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589–95.
Filatenkov A, Baker J, Mueller AMS, Kenkel J, Ahn GO, Dutt S, et al. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin Cancer Res. 2015;21(16):3727–39.
Golden EB, Apetoh L. Radiotherapy and immunogenic cell death. Semin Radiat Oncol. 2015;25(1):11–7.
Buchwald ZS, Wynne J, Nasti TH, Zhu S, Mourad WF, Yan W, et al. Radiation, immune checkpoint blockade and the abscopal effect: a critical review on timing, dose and fractionation. Front Oncol. 2018;8:612.
Rodriguez-Ruiz ME, Vanpouille-Box C, Melero I, Formenti SC, Demaria S. Immunological mechanisms responsible for radiation-induced abscopal effect. Trends Immunol. 2018;39(8):644–55.
Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15(17):5379–88.
Niknam S, Barsoumian HB, Schoenhals JE, Jackson HL, Yanamandra N, Caetano MS, et al. Radiation followed by OX40 stimulation drives local and abscopal antitumor effects in an anti–PD1-resistant lung tumor model. Clin Cancer Res. 2018;24(22):5735–43.
Qu Y, Jin S, Zhang A, Zhang B, Shi X, Wang J, et al. Gamma-ray resistance of regulatory CD4 + CD25 + Foxp3 + T cells in mice. Radiat Res. 2010;173(2):148–57.
Baba J, Watanabe S, Saida Y, Tanaka T, Miyabayashi T, Koshio J, et al. Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia. Blood. 2012;120(12):2417–27.
Qu Y, Zhang B, Liu S, Zhang A, Wu T, Zhao Y. 2-Gy whole-body irradiation significantly alters the balance of CD4 +CD25-T effector cells and CD4+CD25 +Foxp3+ T regulatory cells in mice. Cell Mol Immunol. 2010;7(6):419–27.
Balogh A, Persa E, Bogdándi EN, Benedek A, Hegyesi H, Sáfrány G, et al. The effect of ionizing radiation on the homeostasis and functional integrity of murine splenic regulatory T cells. Inflamm Res. 2013;62(2):201–12.
Billiard F, Buard V, Benderitter M, Linard C. Abdominal γ-radiation induces an accumulation of function-impaired regulatory T cells in the small intestine. Int J Radiat Oncol Biol Phys. 2011;80(3):869–76.
Muroyama Y, Nirschl TR, Kochel CM, Lopez-Bujanda Z, Theodros D, Mao W, et al. Stereotactic radiotherapy increases functionally suppressive regulatory T cells in the tumor microenvironment. Cancer Immunol Res. 2017;5(11):992–1004.
Kachikwu EL, Iwamoto KS, Liao YP, Demarco JJ, Agazaryan N, Economou JS, et al. Radiation enhances regulatory T cell representation. Int J Radiat Oncol Biol Phys. 2011;81(4):1128–35.
Cao M, Cabrera R, Xu Y, Liu C, Nelson D. Gamma irradiation alters the phenotype and function of CD4+CD25+ regulatory T cells. Cell Biol Int. 2009;33(5):565–71.
Liu R, Xiong S, Zhang L, Chu Y. Enhancement of antitumor immunity by low-dose total body irradiation is associated with selectively decreasing the proportion and number of T regulatory cells. Cell Mol Immunol. 2010;7(2):157–62.
Anderson BE, McNiff JM, Matte C, Athanasiadis I, Shlomchik WD, Shlomchik MJ. Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease. Blood. 2004;104(5):1565–73.
Komatsu N, Hori S. Full restoration of peripheral Foxp3+ regulatory T cell pool by radioresistant host cells in scurfy bone marrow chimeras. Proc Natl Acad Sci U S A. 2007;104(21):8959–64.
Cao M, Cabrera R, Xu Y, Liu C, Nelson D. Different radiosensitivity of CD4+CD25+ regulatory T cells and effector T cells to low dose gamma irradiation in vitro. Int J Radiat Biol. 2011;87(1):71–80.
Schmidt A, Eriksson M, Shang MM, Weyd H, Tegnér J. Comparative analysis of protocols to induce human CD4+Foxp3+ regulatory T cells by combinations of IL-2, TGF-beta, retinoic acid, rapamycin and butyrate. PLoS One. 2016;11(2):1–31.
Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775–87.
Zhou L, Chong MMW, Littman DR. Plasticity of CD4+ T cell lineage differentiation. Immunity. 2009;30(5):646–55.
Wei G, Wei L, Zhu J, Zang C, Hu-li J, Yao Z, et al. Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells. Immunity. 2009;30(1):155–67.
Haribhai D, Williams JB, Jia S, Nickerson D, Schmitt EG, Edwards B, et al. A requisite role for induced regulatory T cells in tolerance based on expanding antigen receptor diversity. Immunity. 2011;35(1):109–22.
Chakir H, Wang H, Lefebvre DE, Webb J, Scott FW. T-bet/GATA-3 ratio as a measure of the Th1/Th2 cytokine profile in mixed cell populations: predominant role of GATA-3. J Immunol Methods. 2003;278(1–2):157–69.
Butcher MJ, Filipowicz AR, Waseem TC, McGary CM, Crow KJ, Magilnick N, et al. Atherosclerosis-driven Treg plasticity results in formation of a dysfunctional subset of plastic IFNγ+ Th1/Tregs. Circ Res. 2016;119(11):1190–203.
Camperio C, Caristi S, Fanelli G, Soligo M, De Porto P, Piccolella E. Forkhead Transcription Factor FOXP3 Upregulates CD25 Expression through Cooperation with RelA/NF-κB. PLoS One. 2012;7(10):e48303.
Kolar P, Knieke K, Hegel JKE, Quandt D, Burmester GR, Hoff H, et al. CTLA-4 (CD152) controls homeostasis and suppressive capacity of regulatory T cells in mice. Arthritis Rheum. 2009;60(1):123–32.
Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A. 2008;105(29):10113–8.
Liang B, Workman C, Lee J, Chew C, Dale BM, Colonna L, et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation Gene-3 engagement of MHC class II. J Immunol. 2008;180(9):5916–26.
Xie X, Stubbington MJT, Nissen JK, Andersen KG, Hebenstreit D, Teichmann SA, et al. The regulatory T cell lineage factor Foxp3 regulates gene expression through several distinct mechanisms mostly independent of direct DNA binding. PLoS Genet. 2015;11(6):1–32.
Sadlon TJ, Wilkinson BG, Pederson S, Brown CY, Bresatz S, Gargett T, et al. Genome-wide identification of human FOXP3 target genes in natural regulatory T cells. J Immunol. 2010;185(2):1071–81.
Huang W, Solouki S, Carter C, Zheng SG, August A. Beyond type 1 regulatory t cells: co-expression of LAG3 and CD49b in IL-10-producing T cell lineages. Front Immunol. 2018;9:1–11.
Kumari A, Simon SS, Moody TD, Garnett-Benson C. Immunomodulatory effects of radiation: what is next for cancer therapy? Future Oncol. 2016;12(2):239–56.
Nakamura N, Kusunoki Y, Akiyama M. Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro Colony formation assay. Radiat Res. 1990;123(2):224.
Lee W, Lee GR. Transcriptional regulation and development of regulatory T cells. Exp Mol Med. 2018;50(3):e456.
Kumari A, Cacan E, Greer SF, Garnett-Benson C. Turning T cells on: epigenetically enhanced expression of effector T-cell costimulatory molecules on irradiated human tumor cells. J Immunother Cancer. 2013;1(1):1.
Cacan E, Greer SF, Garnett-Benson C. Radiation-induced modulation of immunogenic genes in tumor cells is regulated by both histone deacetylases and DNA methyltransferases. Int J Oncol. 2015;47(6):2264–75.
Miousse IR, Kutanzi KR, Koturbash I. Effects of ionizing radiation on DNA methylation: From experimental biology to clinical applications. Int J Radiat Biol. 2017;93(5):457–69.
Chen Q, Kim YC, Laurence A, Punkosdy GA, Shevach EM. IL-2 controls the stability of Foxp3 expression in TGF-β–induced Foxp3 + T cells in vivo. J Immunol. 2011;186(11):6329–37.
Goldstein JD, Burlion A, Zaragoza B, Sendeyo K, Polansky JK, Huehn J, et al. Inhibition of the JAK/STAT signaling pathway in regulatory T cells reveals a very dynamic regulation of foxp3 expression. PLoS One. 2016;11(4):1–16.
Bazhin AV, von Ahn K, Fritz J, Werner J, Karakhanova S. Interferon-α up-regulates the expression of PD-L1 molecules on immune cells through STAT3 and p38 signaling. Front Immunol. 2018;9:2129.
Amarnath S, Costanzo CM, Mariotti J, Ullman JL, Telford WG, Kapoor V, et al. Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1. PLoS Biol. 2010;8(2):e1000302.
Regateiro FS, Howie D, Nolan KF, Agorogiannis EI, Greaves DR, Cobbold SP, et al. Generation of anti-inflammatory adenosine byleukocytes is regulated by TGF-β. Eur J Immunol. 2011;41(10):2955–65.
Peres RS, Donate PB, Talbot J, Cecilio NT, Lobo PR, Machado CC, et al. TGF-β signalling defect is linked to low CD39 expression on regulatory T cells and methotrexate resistance in rheumatoid arthritis. J Autoimmun. 2018;90:49–58.
Sim GC, Martin-Orozco N, Jin L, Yang Y, Wu S, Washington E, et al. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J Clin Invest. 2014;124(1):99–110.
Morisada M, Clavijo PE, Moore E, Sun L, Chamberlin M, Van Waes C, et al. PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation. Oncoimmunology. 2018;7(3):1–10.
Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618.
Sridharan V, Margalit DN, Lynch SA, Severgnini M, Zhou J, Chau NG, et al. Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. Br J Cancer. 2016;115(2):252–60.
Okamura T, Fujio K, Shibuya M, Sumitomo S, Shoda H, Sakaguchi S, et al. CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2. Proc Natl Acad Sci U S A. 2009;106(33):13974–9.
Durham NM, Nirschl CJ, Jackson CM, Elias J, Kochel CM, Anders RA, et al. Lymphocyte activation gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo. PLoS One. 2014;9(11):1–13.
Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest. 2007;117(11):3383–92.
Lichtenegger FS, Rothe M, Schnorfeil FM, Deiser K, Krupka C, Augsberger C, et al. Targeting LAG-3 and PD-1 to enhance T cell activation by antigen-presenting cells. Front Immunol. 2018;9(FEB):1–12.
Zhang Q, Chikina M, Szymczak-Workman AL, Horne W, Kolls JK, Vignali KM, et al. LAG-3 limits regulatory T cell proliferation and function in autoimmune diabetes. Sci Immunol. 2017;2(9):eaah4569.
Venken K, Thewissen M, Hellings N, Somers V, Hensen K, Rummens JL, et al. A CFSE based assay for measuring CD4+CD25+ regulatory T cell mediated suppression of auto-antigen specific and polyclonal T cell responses. J Immunol Methods. 2007;322(1–2):1–11.
This work was supported by a Research Scholar Grant from the American Cancer Society to C. Garnett-Benson (RSG-15-182-01). The funding body was not involved in the design of this study, data collection, data interpretation, or in the writing of this manuscript.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The original version of this article was revised as some of the bars of Fig. 4 were missing from the published version.
About this article
Cite this article
Beauford, S.S., Kumari, A. & Garnett-Benson, C. Ionizing radiation modulates the phenotype and function of human CD4+ induced regulatory T cells. BMC Immunol 21, 18 (2020). https://doi.org/10.1186/s12865-020-00349-w
- Regulatory T cells
- Cancer immunotherapy